Loading...
XHKG
1789
Market cap881mUSD
Jun 13, Last price  
6.20HKD
1D
-1.59%
1Q
15.67%
IPO
132.21%
Name

AK Medical Holdings Ltd

Chart & Performance

D1W1MN
P/E
23.11
P/S
4.70
EPS
0.25
Div Yield, %
0.73%
Shrs. gr., 5y
1.12%
Rev. gr., 5y
7.76%
Revenues
1.35b
+23.08%
148,278,000206,164,000270,777,000372,700,000600,562,000926,705,0001,035,386,000761,441,0001,052,047,0001,093,862,0001,346,377,000
Net income
274m
+50.42%
51,721,00064,907,00077,326,000105,376,000144,936,000266,992,000314,007,00092,619,000204,772,000182,104,000273,926,000
CFO
0k
-100.00%
51,092,00036,302,00069,643,000116,652,000127,992,000144,662,000205,257,000176,621,000242,919,00033,935,0000
Dividend
Jun 23, 20250.072 HKD/sh

Profile

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products under the AK Medical brand in China and internationally. It offers knee, hip, and spine replacement implants; and 3D-printed products, such as 3D-printed hip replacement implants, 3D-printed artificial vertebral bodies, and 3D-printed spinal interbody cages. The company also distributes third party orthopedic products; and manufactures surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is headquartered in Beijing, the People's Republic of China. AK Medical Holdings Limited is a subsidiary of Ximalaya Limited.
URL
https://www.ak-medical.net/index.html
IPO date
Dec 20, 2017
Employees
1,082
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,346,377
23.08%
1,093,862
3.97%
1,052,047
38.17%
Cost of revenue
1,062,250
908,749
824,897
Unusual Expense (Income)
NOPBT
284,127
185,113
227,150
NOPBT Margin
21.10%
16.92%
21.59%
Operating Taxes
45,896
49,013
35,518
Tax Rate
16.15%
26.48%
15.64%
NOPAT
238,231
136,100
191,632
Net income
273,926
50.42%
182,104
-11.07%
204,772
121.09%
Dividends
(61,509)
(23,962)
Dividend yield
0.88%
0.22%
Proceeds from repurchase of equity
8,933
10,774
BB yield
-0.13%
-0.10%
Debt
Debt current
72,570
35,633
13,500
Long-term debt
48,094
79,120
64,062
Deferred revenue
13,331
Other long-term liabilities
73,977
64,378
8,324
Net debt
(927,261)
(611,919)
(1,599,175)
Cash flow
Cash from operating activities
33,935
242,919
CAPEX
(183,796)
(121,717)
Cash from investing activities
(318,148)
(82,294)
Cash from financing activities
(14,021)
(36,796)
FCF
266,561
198,229
150,524
Balance
Cash
1,047,925
726,672
1,042,422
Long term investments
634,315
Excess cash
980,606
671,979
1,624,135
Stockholders' equity
2,638,186
1,404,729
1,235,120
Invested Capital
1,830,946
1,868,505
1,020,308
ROIC
12.88%
9.42%
19.10%
ROCE
10.11%
7.29%
9.86%
EV
Common stock shares outstanding
1,118,670
1,119,189
1,117,457
Price
4.85
-22.52%
6.26
-36.06%
9.79
48.33%
Market cap
5,425,552
-22.56%
7,006,124
-35.96%
10,939,908
47.92%
EV
4,498,291
6,394,205
9,340,733
EBITDA
284,127
276,052
307,551
EV/EBITDA
15.83
23.16
30.37
Interest
1,287
2,174
Interest/NOPBT
0.70%
0.96%